Clinical trials: Chemoradiation
Carcinoma, Non-Small-Cell Lung
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab…
- Trial name
- RATIONALE001 (NCT03745222)
- Testing
- Tislelizumab, Concurrent chemoradiotherapy (cCRT)
- Where
- 164 sites in United States, Belgium and 21 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
Oral Mucositis, Head and Neck Cancer
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).
- Trial name
- NCT00574860
- Testing
- EN3285, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Head and Neck Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis in subjects with locally advanced head and…
- Trial name
- NCT00131638
- Testing
- Palifermin
- Volunteers
- 241 people
- Sponsor
- Amgen
Locally Advanced Cervical Carcinoma
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer
- Trial name
- AK104-305 (NCT05235516)
- Testing
- AK104, EBRT, BT
- Where
- 9 sites in China
- Volunteers
- 636 people
- Sponsor
- Akeso
Oral Mucositis, Quality of Life
Retrospective Observational Study of Oral Complications and Quality of Life in Head and Neck Cancer Patients Treated With Radiotherapy or Chemoradiotherapy.
Head and Neck cancer patients receiving radiation therapy (with or without chemotherapy) suffer several oral complications, such as oral mucositis, which impairs quality of life of patients during radiotherapy and in the…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- NCT07739771
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Mucosa Innovations, S.L.
Esophageal Carcinoma
A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma
This multicentered clinical trial is going to find out the radio-sensitization action of sodium glycididazole in radiochemotherapy for esophageal cancer.
- Trial name
- NCT00642239
- Testing
- Sodium Glycididazole
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Shandong Luye Pharmaceutical Co., Ltd.
Stage III Non-small-cell Lung Cancer
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as…
- Trial name
- NCT04325763
- Testing
- TQB2450, Anlotinib, TQB2450(blank)
- Where
- 36 sites in China
- Volunteers
- 315 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glioblastoma Multiforme
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).
- Trial name
- NCT01280552
- Testing
- ICT-107
- Where
- 25 sites in United States
- Volunteers
- 124 people
- Sponsor
- Precision Life Sciences Group
Rectal Cancer
Pre-op Rectal ChemoRad +/- Cetuximab
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
- Trial name
- NCT00527111
- Testing
- Cetuximab, 5-fluorouracil, Pelvic irradiation
- Where
- 41 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Oncology Research
Head and Neck Cancer
Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients
The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation…
- Trial name
- SYMTECH01 (NCT06385587)
- Testing
- Oleena
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Aptar Digital Health
Breast Cancer
Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects
This trial will be the first trial for the IP, [F-18]CP-18, and will be conducted as an exploratory Phase I trial designed to collect information as this IP is administered and evaluated for the first time in humans.
- Trial name
- NCT01362712
- Testing
- [F18]CP-18 Injection
- Where
- 3 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Locally Advanced Esophageal or GE Junction Cancer
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
- Trial name
- NCT00561197
- Testing
- AT-101
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ascenta Therapeutics
Oral Mucositis
A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients
This study is a randomized, double-blind, sham-controlled, two-arm study conducted in subjects receiving chemoradiation therapy for the treatment of head and neck cancer to assess the efficacy of MuGard.
- Trial name
- MuGard (NCT01283906)
- Testing
- MuGard, Control Rinse
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Access Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant…
- Trial name
- MDT-BRIDGE (NCT05925530)
- Testing
- Durvalumab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
- Trial name
- NCT00237900
- Testing
- Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
- Where
- Finland
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Rectal Neoplasms
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
Primary: To assess complete pathological response rate of both strategies. Secondary: Safety profile To assess downstaging rate of both strategies.
- Trial name
- NCT00421824
- Testing
- Oxaliplatin, capecitabine
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Sanofi
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Non-Squamous Non-Small Cell Lung Cancer
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will assess the feasibility of use, safety and tolerability of Avastin(bevacizumab) in combination with chemoradiation therapy in patients with locally advanced unresectable non-squamous non-small cell lung…
- Trial name
- NCT00773188
- Testing
- bevacizumab [Avastin], cisplatin, vinorelbine
- Where
- 4 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche